Navigation Links
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
Date:5/21/2008

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase II trial for primary liver cancer, demonstrated promising Phase I efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit http://www.jennerex.com.

About Green Cross Corporation

Green Cross is a leader in the Korean biotechnology and pharmaceutical industries. Green Cross is now an internationally recognized biotechnology company developing several vaccines and therapeutic proteins. Green Cross will become the only seasonal influenza vaccine manufacturer in South Korea and also is developing avian influenza vaccine. In its vaccine business, Green Cross has successfully developed one of the earliest vaccines against Hepatitis B (Hepavax), the first Epidemic Hemorrhagic Fever vaccine and the world's second chicken pox vaccine. Green Cross is developing anticancer drugs such as Greenstatin (anti-angiogenic peptide) and modified PEG-G-CSF for neutropenia.


'/>"/>
SOURCE Jennerex
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
7. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Promising Cystic Fibrosis Compound on Track for Development
11. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... BD (Becton, Dickinson and Company) (NYSE: ... of Waste Management, Inc. (NYSE: WM ), ... from hospitals and other healthcare facilities.  The companies are ... innovative service that will recycle medical sharps waste and ...
... -- The 109th Session Canton Fair will officially commence on ... conclude on May 5.   Buyers attending Canton ... China is upgrading its manufacturing industry, which will benefit ... exhibitors have invested significantly in R&D and development of their ...
Cached Medicine Technology:BD and Waste Management Launch Initiative to Recycle Medical Sharps 2BD and Waste Management Launch Initiative to Recycle Medical Sharps 3BD and Waste Management Launch Initiative to Recycle Medical Sharps 4Canton Fair: China's Greatest Trade Fair to Open in April 2
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... (SACRAMENTO, Calif.) An international team led by researchers ... protein complex, which plays a key role in cell ... process. This is the first time the complex has ... could make cyclin B1/Cdk1 an excellent target to control ... medicine. The research was published online today in the ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... is open for the 2010 AIUM Annual Convention and ... United States dedicated to all disciplines of medical ultrasound, ... California. The 2010 Annual Convention focuses on emerging applications ... and manufacturers as ultrasound continues to advance and expand ...
... target for the most common form of ovarian cancer. ... the research team describes finding that a gene called MAGP2 ... was overexpressed in papillary serous ovarian tumors of patients who ... mechanisms by which MAGP2 may promote tumor growth. ...
... from high-flow oxygen treatment , TUESDAY, Dec. 8 ... effective treatment for cluster headaches, British researchers have found. ... as eight per day in bouts that last for ... the drug sumatriptan, but frequent use of the drug ...
... of death, recurrence , TUESDAY, Dec. 8 (HealthDay News) -- ... risk of death and cancer recurrence in women who,ve had ... between soy and a reduced risk of death held true ... tamoxifen, according to the study published in the Dec. 9 ...
... , STRONGSVILLE, Ohio, Dec. 8 ... way it conducts business and services customers earning an ISO ... management standard for organizations. The basis for the standard is ... a valued asset, information must be managed and protected from ...
... , SAN FRANCISCO, Dec. 8 Quantros, a leading ... published a whitepaper addressing the ramifications for healthcare organizations ... 2005 (PSQIA), the legislation that authorized the creation of ... providers contemplating participation in a PSO, Patient Safety ...
Cached Medicine News:Health News:AIUM gears up for 2010 Annual Convention in San Diego, California 2Health News:Possible ovarian cancer treatment target identified 2Health News:Oxygen Therapy May Relieve Cluster Headache Pain 2Health News:Soy Beneficial for Breast Cancer Survivors: Study 2Health News:Soy Beneficial for Breast Cancer Survivors: Study 3Health News:Antares Achieves ISO Certification 2Health News:Patient Safety Organization (PSO) Participation: What Every Provider Needs to Know 2
... telescoping plate design integrates the ... and vertebral column spacer. This ... need for supplemental fixation while ... bone graft to be delivered ...
... Tendril ST leads ... pacing leads, designed to ... reliability and flexibility to ... These pre-formed "J leads ...
The MYO-VAD is a novel cardiac support system with unique, life-saving features....
... revolutionary technology provides full picture ,CardioPAL ... incorporate true Artifi cial Intelligence, with a ... in the background, on each device. The ... activity based on rate, rhythm, morphology, and ...
Medicine Products: